{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:25:11Z","timestamp":1793982311069,"version":"4.8.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"22","license":[{"start":{"date-parts":[[2017,9,9]],"date-time":"2017-09-09T00:00:00Z","timestamp":1504915200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100015756","name":"Janssen Cilag","doi-asserted-by":"crossref","award":["Independent Educational Grant"],"award-info":[{"award-number":["Independent Educational Grant"]}],"id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00213-017-4730-6","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T11:48:30Z","timestamp":1505130510000},"page":"3279-3297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research"],"prefix":"10.1007","volume":"234","author":[{"given":"Jasmin","family":"Grigg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"Worsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Thew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gurvich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashri","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,9]]},"reference":[{"issue":"6","key":"4730_CR1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","volume":"22","author":"T Baptista","year":"2008","unstructured":"Baptista T, ElFakih Y, Uzc\u00e1tegui E, Sandia I, T\u00e1lamo E, de Baptista EA, Beaulieu S (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22(6):477\u2013495","journal-title":"CNS Drugs"},{"issue":"5","key":"4730_CR2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25(5):567\u2013620","journal-title":"J Psychopharmacol"},{"key":"4730_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ajp.2016.01.012","volume":"21","author":"T Bastiampillai","year":"2016","unstructured":"Bastiampillai T, Gupta A, Allison S (2016) FDA changes clozapine monitoring guidelines: implications for worldwide practice. Asian J Psychiatr 21:19\u201320","journal-title":"Asian J Psychiatr"},{"key":"4730_CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.psychres.2016.01.031","volume":"237","author":"QJ Bo","year":"2016","unstructured":"Bo QJ, Wang ZM, Li XB, Ma X, Wang CY, de Leon J (2016) Adjunctive metformin for antipsychotic-induced hyperprolactinemia: a systematic review. Psychiatry Res 237:257\u2013263","journal-title":"Psychiatry Res"},{"issue":"81","key":"4730_CR5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.maturitas.2015.02.192","volume":"1","author":"J Brockie","year":"2015","unstructured":"Brockie J, Brown R (2015) Antipsychotic-induced hyperprolactinaemia: adapting guidelines to overcome challenges posed by this group of women. Maturitas 1(81):164\u2013165","journal-title":"Maturitas"},{"key":"4730_CR6","unstructured":"Brouwers JR, Assies J, Wiersinga WM, Huizing G, Tytgat GN, et al. (2010) Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: a cross-over study in healthy volunteers. Clin. Endocrinol. 12.5 (May 1980):435\u2013440."},{"key":"4730_CR7","unstructured":"Brown, R. and V. Frighi (2015). Antipsychotic-induced hyperprolactinaemia - trust guideline for identification, monitoring and management, Oxford Health: NHS Foundation Trust"},{"issue":"1","key":"4730_CR8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71\u201393","journal-title":"Schizophr Bull"},{"issue":"4","key":"4730_CR9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1258\/acb.2010.010025","volume":"47","author":"CJ Bushe","year":"2010","unstructured":"Bushe CJ, Bradley A, Pendlebury J (2010) A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem 47(4):292\u2013300","journal-title":"Ann Clin Biochem"},{"issue":"8","key":"4730_CR10","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","volume":"34","author":"C-K Chen","year":"2010","unstructured":"Chen C-K, Huang Y-S, Ree S-C, Hsiao C-C (2010) Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry 34(8):1495\u20131499","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"4730_CR11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004714-198704000-00008","volume":"7","author":"N Correa","year":"1987","unstructured":"Correa N, Opler L, Kay S, Birmaher B (1987) Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 7(2):91\u201394","journal-title":"J Clin Psychopharmacol"},{"key":"4730_CR12","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","volume":"25","author":"C Correll","year":"2010","unstructured":"Correll C (2010) From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25:S12\u2013S21","journal-title":"Eur Psychiatry"},{"issue":"9","key":"4730_CR13","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2013.13060771","volume":"170","author":"CU Correll","year":"2013","unstructured":"Correll CU, Sikich L, Reeves G, Riddle M (2013) Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? Am J Psychiatr 170(9):947\u2013952","journal-title":"Am J Psychiatr"},{"issue":"3","key":"4730_CR14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/schbul\/sbv001","volume":"41","author":"MK Boer de","year":"2015","unstructured":"de Boer MK, Castelein S, Wiersma D, Schoevers RA, Knegtering H (2015) The facts about sexual (dys) function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull 41(3):674\u2013686","journal-title":"Schizophr Bull"},{"issue":"6","key":"4730_CR15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14740338.2016.1167873","volume":"15","author":"M Hert De","year":"2016","unstructured":"De Hert M, Detraux J, Stubbs B (2016a) Relationship between antipsychotic medication, serum prolactin levels and osteoporosis\/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opin Drug Saf 15(6):809\u2013823","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"4730_CR16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/acps.12459","volume":"133","author":"M Hert De","year":"2016","unstructured":"De Hert M, Peuskens J, Sabbe T, Mitchell A, Stubbs B, Neven P, Wildiers H, Detraux J (2016b) Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand 133(1):5\u201322","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"4730_CR17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/13697137.2013.795683","volume":"16","author":"T Villiers De","year":"2013","unstructured":"De Villiers T, Pines A, Panay N, Gambacciani M, Archer D, Baber R, Davis S, Gompel A, Henderson V, Langer R (2013) Updated 2013 international menopause society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 16(3):316\u2013337","journal-title":"Climacteric"},{"issue":"1","key":"4730_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-12-20","volume":"12","author":"M DiBonaventura","year":"2012","unstructured":"DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E (2012) A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry 12(1):1","journal-title":"BMC Psychiatry"},{"issue":"10","key":"4730_CR19","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4088\/JCP.09m05274yel","volume":"71","author":"M Ehret","year":"2010","unstructured":"Ehret M, Goethe J, Lanosa M, Coleman CI (2010) The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry 71(10):1286\u20131292","journal-title":"J Clin Psychiatry"},{"key":"4730_CR20","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1016\/j.eurpsy.2016.01.631","volume":"33","author":"C Franch","year":"2016","unstructured":"Franch C, Medina G, Ortega M, Calzada M, Molina V (2016) Problems in long-term treatment with atypical antipsychotics: hyperprolactinemia. Eur Psychiatry 33:S248\u2013S249","journal-title":"Eur Psychiatry"},{"issue":"4","key":"4730_CR21","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1152\/physrev.2000.80.4.1523","volume":"80","author":"ME Freeman","year":"2000","unstructured":"Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80(4):1523\u20131631","journal-title":"Physiol Rev"},{"issue":"12","key":"4730_CR22","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/npp.2010.111","volume":"35","author":"W Gaebel","year":"2010","unstructured":"Gaebel W, Schreiner A, Bergmans P, De Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E (2010) Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35(12):2367","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"4730_CR23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/0004867416641195","volume":"50","author":"C Galletly","year":"2016","unstructured":"Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen O, Tran N (2016) Royal Australian and new Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50(5):410\u2013472","journal-title":"Aust N Z J Psychiatry"},{"key":"4730_CR24","doi-asserted-by":"crossref","unstructured":"Gentile, S. (2017). Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update. Hormone Molecular Biology and Clinical Investigation","DOI":"10.1515\/hmbci-2017-0004"},{"key":"4730_CR25","doi-asserted-by":"crossref","unstructured":"Gomes, P. L., V. S. Nunes, \u00c1. N. Atallah and E. M. da Silva (2012) Dopamine agonists for hyperprolactinaemia. The Cochrane Library","DOI":"10.1002\/14651858.CD009718"},{"key":"4730_CR26","doi-asserted-by":"crossref","unstructured":"Grigg, J., R. Worsley and J. Kulkarni (2016). Raloxifene for schizophrenia and symptoms of hyperprolactinaemia? Aust N Z J Psychiatry: 0004867416670014","DOI":"10.1177\/0004867416670014"},{"issue":"3","key":"4730_CR27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","volume":"14","author":"H Grunze","year":"2013","unstructured":"Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, M\u00f6ller H-J, Kasper S (2013) The world Federation of Societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14(3):154\u2013219","journal-title":"World J Biol Psychiatry"},{"key":"4730_CR28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","volume":"28","author":"U Halbreich","year":"2003","unstructured":"Halbreich U, Kinon B, Gilmore J, Kahn L (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28:53\u201367","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"4730_CR29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, M\u00f6ller H-J (2013) World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 14(1):2\u201344","journal-title":"World J Biol Psychiatry"},{"issue":"5","key":"4730_CR30","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3923\/ijp.2010.691.695","volume":"6","author":"S Hasani-Ranjbar","year":"2010","unstructured":"Hasani-Ranjbar S, Vahidi H, Taslimi S, Karimi N, Larijani B, Abdollahi M (2010) A systematic review on the efficacy of herbal medicines in the management of human drug-induced hyperprolactinemia; potential sources for the development of novel drugs. IJP Int J Pharmacol 6(5):691\u2013695","journal-title":"IJP Int J Pharmacol"},{"issue":"1","key":"4730_CR31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","volume":"10","author":"M Hert","year":"2011","unstructured":"Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, M\u00f6ller HJ, Ndetei DM (2011) Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10(1):52\u201377","journal-title":"World Psychiatry"},{"issue":"4","key":"4730_CR32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/appi.psy.50.4.317","volume":"50","author":"ZS Hoffer","year":"2009","unstructured":"Hoffer ZS, Roth RL, Mathews M (2009) Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 50(4):317\u2013324","journal-title":"Psychosomatics"},{"issue":"10","key":"4730_CR33","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","volume":"45","author":"WJ Inder","year":"2011","unstructured":"Inder WJ, Castle D (2011) Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 45(10):830\u2013837","journal-title":"Aust N Z J Psychiatry"},{"key":"4730_CR34","unstructured":"Institute of Medicine (U.S.) (2011) Committee on standards for developing trustworthy clinical practice guidelines. In: Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E (eds) Clinical practice guidelines we can trust. National Academies Press, Washington"},{"key":"4730_CR35","doi-asserted-by":"publisher","unstructured":"Institute of Medicine (1990) Committee to advise the public health service on clinical practice guidelines. In: Field MJ, Lohr KN (eds) Clinical Practice Guidelines: Directions for a New Program. The National Academies Press, Washington. https:\/\/doi.org\/10.17226\/1626","DOI":"10.17226\/1626"},{"issue":"6","key":"4730_CR36","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/JCP.0b013e31818ba5d8","volume":"28","author":"E Johnsen","year":"2008","unstructured":"Johnsen E, Kroken RA, Abaza M, Olberg H, J\u00f8rgensen HA (2008) Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J Clin Psychopharmacol 28(6):686\u2013690","journal-title":"J Clin Psychopharmacol"},{"issue":"628","key":"4730_CR37","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3399\/bjgp14X682213","volume":"64","author":"E Jones","year":"2014","unstructured":"Jones E (2014) Antipsychotics and osteoporosis: current awareness and practice in primary care. Br J Gen Pract 64(628):562","journal-title":"Br J Gen Pract"},{"key":"4730_CR38","doi-asserted-by":"crossref","unstructured":"Kolli, V. B., D. P. Bestha, V. Madaan and S. Byreddy (2013) Aripiprazole for neuroleptic induced hyperprolactinaemia. The Cochrane Library","DOI":"10.1002\/14651858.CD010786"},{"key":"4730_CR39","unstructured":"Kotecha, P. (2013). Guidelines for the management of antipsychotic-induced hyperprolactinaemia MMG007. Northamptonshire, Northamptonshire Healthcare, NHS Foundation Trust"},{"issue":"9","key":"4730_CR40","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamapsychiatry.2016.1383","volume":"73","author":"J Kulkarni","year":"2016","unstructured":"Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M, Davis SR (2016) Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry 73(9):947\u2013954","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"4730_CR41","doi-asserted-by":"crossref","first-page":"e94788","DOI":"10.1371\/journal.pone.0094788","volume":"9","author":"J Kulkarni","year":"2014","unstructured":"Kulkarni J, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen TE, Wang W, McCauley K, Fitzgerald P (2014) A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One 9(5):e94788","journal-title":"PLoS One"},{"issue":"5","key":"4730_CR42","first-page":"929","volume":"3","author":"D Torre La","year":"2007","unstructured":"La Torre D, Falorni A (2007) Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 3(5):929","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"4730_CR43","doi-asserted-by":"crossref","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","volume":"8","author":"X Li","year":"2013","unstructured":"Li X, Tang Y, Wang C (2013) Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One 8(8):e70179","journal-title":"PLoS One"},{"issue":"12","key":"4730_CR44","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209\u20131223","journal-title":"N Engl J Med"},{"issue":"2","key":"4730_CR45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4730_CR46","first-page":"4","volume":"27","author":"M Meng","year":"2015","unstructured":"Meng M, Li W, Zhang S, Weng H, Sheng J, Wang J, Li C (2015) Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry 27(1):4","journal-title":"Shanghai Arch Psychiatry"},{"issue":"1","key":"4730_CR47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/157488711793980138","volume":"6","author":"W Milano","year":"2011","unstructured":"Milano W, Walter D'Acunto C, De Rosa M, Festa M, Milano L, Petrella C, Capasso A (2011) Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Rev Recent Clin Trials 6(1):52\u201364","journal-title":"Rev Recent Clin Trials"},{"issue":"2","key":"4730_CR48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40501-017-0115-z","volume":"4","author":"S Miyamoto","year":"2017","unstructured":"Miyamoto S, Fleischhacker WW (2017) The use of long-acting injectable antipsychotics in schizophrenia. Curr Treat Options Psychiatry 4(2):117\u2013126","journal-title":"Curr Treat Options Psychiatry"},{"key":"4730_CR49","doi-asserted-by":"crossref","unstructured":"Montejo, \u00c1., C. Arango, M. Bernardo, J. Carrasco, B. Crespo-Facorro, J. Cruz, J. Del Pino, E. M. Garc\u00eda, R. C. Garc\u00eda and A. Gonz\u00e1lez-Pinto (2016). Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. Revista de psiquiatria y salud mental","DOI":"10.1016\/j.rpsmen.2016.06.001"},{"issue":"7","key":"4730_CR50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/15622975.2015.1012225","volume":"17","author":"A Murru","year":"2016","unstructured":"Murru A, Hidalgo D, Bernardo M, Bobes J, Saiz-Ruiz J, \u00c1lamo C, Vieta E (2016) Antipsychotic switching in schizoaffective disorder: a systematic review. World J Biol Psychiatry 17(7):495\u2013513","journal-title":"World J Biol Psychiatry"},{"key":"4730_CR51","unstructured":"National Institute for Clinical Excellence (2014) Psychosis and schizophrenia in adults: prevention and management; National Clinical Practice Guidelines Number CG178: 1\u201358"},{"key":"4730_CR52","unstructured":"National Institute for Health and Care Excellence (2014) (Updated 2016) Bipolar disorder: assessment and management (Clinical guideline)."},{"key":"4730_CR53","unstructured":"NHS Foundation Trust (2015) Hyperprolactinaemia: guidelines for patients and clinicians (PHARM\/0032\/V5), Tees, Esk and Wear Valleys: NHD Foundation Trust"},{"issue":"8","key":"4730_CR54","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.euroneuro.2015.04.007","volume":"25","author":"I Pacchiarotti","year":"2015","unstructured":"Pacchiarotti I, Murru A, Kotzalidis GD, Bonnin CM, Mazzarini L, Colom F, Vieta E (2015) Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol 25(8):1045\u20131059","journal-title":"Eur Neuropsychopharmacol"},{"key":"4730_CR55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.psychres.2016.03.015","volume":"239","author":"Y-M Park","year":"2016","unstructured":"Park Y-M, Lee S-H, Lee B-H, Lee KY, Lee K-S, Kang S-G, Lee H-Y, Kim W (2016) Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study. Psychiatry Res 239:184\u2013189","journal-title":"Psychiatry Res"},{"key":"4730_CR56","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(98)00158-3","volume":"35","author":"RG Petty","year":"1999","unstructured":"Petty RG (1999) Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 35:S67\u2013S73","journal-title":"Schizophr Res"},{"issue":"5","key":"4730_CR57","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 28(5):421\u2013453","journal-title":"CNS Drugs"},{"key":"4730_CR58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0269881107087346","volume":"22","author":"RC Peveler","year":"2008","unstructured":"Peveler RC, Branford D, Citrome L, Fitzgerald P, Harvey PW, Holt RI, Howard L, Kohen D, Jones I, Pariente CM (2008) Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 22:98\u2013104","journal-title":"J Psychopharmacol"},{"issue":"6","key":"4730_CR59","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.endonu.2012.11.005","volume":"60","author":"IH Rabinovich","year":"2013","unstructured":"Rabinovich IH, G\u00f3mez RC, Mouriz MG, Garc\u00eda-Agull\u00f3 DO (2013) Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia. Endocrinol Nutr (Engl Ed) 60(6):308\u2013319","journal-title":"Endocrinol Nutr (Engl Ed)"},{"issue":"1","key":"4730_CR60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000329028","volume":"65","author":"JK Rybakowski","year":"2011","unstructured":"Rybakowski JK, Dmitrzak-Weglarz M, Kapelski P, Hauser J (2011) Functional\u20131149 G\/T polymorphism of the prolactin gene in schizophrenia. Neuropsychobiology 65(1):41\u201344","journal-title":"Neuropsychobiology"},{"key":"4730_CR61","doi-asserted-by":"crossref","unstructured":"Skovlund CW, M\u00f8rch LS, Kessing LV, Lidegaard \u00d8 (2016) Association of Hormonal Contraception with Depression. JAMA Psychiatry","DOI":"10.1001\/jamapsychiatry.2016.2387"},{"key":"4730_CR62","doi-asserted-by":"crossref","unstructured":"Soto-Pedre, E., P. J. Newey, J. S. Bevan, N. Greig and G. P. Leese (2016). The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the prolactin epidemiology, audit and research study (PROLEARS). Clinical Endocrinology","DOI":"10.1111\/cen.13156"},{"key":"4730_CR63","volume-title":"The Maudsley prescribing guidelines in psychiatry","author":"D Taylor","year":"2015","unstructured":"Taylor D, Paton C, Kapur S (2015) The Maudsley prescribing guidelines in psychiatry. Wiley Blackwell, West Sussex"},{"issue":"4","key":"4730_CR64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.9740\/mhc.2016.07.185","volume":"6","author":"A Tewksbury","year":"2016","unstructured":"Tewksbury A, Olander A (2016) Management of antipsychotic-induced hyperprolactinemia. Mental Health Clin 6(4):185\u2013190","journal-title":"Mental Health Clin"},{"key":"4730_CR65","volume-title":"Guidance on the treatment of antipsychotic-induced Hyperprolactinaemia, version 2","author":"N Tomova","year":"2016","unstructured":"Tomova N, Whale R, Caldwell G (2016) Guidance on the treatment of antipsychotic-induced Hyperprolactinaemia, version 2. Sussex Partnership: NHS Foundation Trust, Sussex"},{"key":"4730_CR66","unstructured":"Usall, J., E. Huerta-Ramos, J. Labad, J. Cobo, C. N\u00fa\u00f1ez, M. Creus, G. G. Par\u00e9s, D. Cuadras, J. Franco and E. Miquel (2015). Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. Schizophrenia bulletin: sbv149"},{"issue":"6","key":"4730_CR67","first-page":"355","volume":"21","author":"A Valevski","year":"1998","unstructured":"Valevski A, Modai I, Zbarski E, Zemishlany Z, Weizman A (1998) Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clin Neuropharmacol 21(6):355\u2013357","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"4730_CR68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/pnp.237","volume":"16","author":"J Walsh","year":"2012","unstructured":"Walsh J, Lees E (2012) Doctors' understanding of antipsychotic associated hyperprolactinaemia. Prog Neurol Psychiatry 16(3):28\u201332","journal-title":"Prog Neurol Psychiatry"},{"issue":"2","key":"4730_CR69","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hup.2387","volume":"29","author":"M Wang","year":"2014","unstructured":"Wang M, Hou R, Jian J, Mi G, Qiu H, Cao B, Tang M (2014) Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol Clin Exp 29(2):183\u2013189","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"12","key":"4730_CR70","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","volume":"59","author":"PS Wang","year":"2002","unstructured":"Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J (2002) Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59(12):1147\u20131154","journal-title":"Arch Gen Psychiatry"},{"issue":"8230","key":"4730_CR71","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(81)92334-5","volume":"317","author":"B Wistedt","year":"1981","unstructured":"Wistedt B, Wiles D, Kolakowska T (1981) Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 317(8230):1163","journal-title":"Lancet"},{"issue":"7182","key":"4730_CR72","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","volume":"318","author":"SH Woolf","year":"1999","unstructured":"Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J (1999) Potential benefits, limitations, and harms of clinical guidelines. Br Med J 318(7182):527","journal-title":"Br Med J"},{"key":"4730_CR73","unstructured":"World Health Organization (2001) The world health report 2001: mental health: new understanding, new hope. World Health Organization, Geneva"},{"issue":"3","key":"4730_CR74","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jsxm.2015.12.014","volume":"13","author":"R Worsley","year":"2016","unstructured":"Worsley R, Santoro N, Miller KK, Parish SJ, Davis SR (2016) Hormones and female sexual dysfunction: beyond estrogens and androgens\u2014findings from the fourth international consultation on sexual medicine. J Sex Med 13(3):283\u2013290","journal-title":"J Sex Med"},{"issue":"1","key":"4730_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O\u2019Donovan C, MacQueen G, McIntyre RS, Sharma V (2013) Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15(1):1\u201344","journal-title":"Bipolar Disord"},{"issue":"2","key":"4730_CR76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","volume":"27","author":"F Yokoi","year":"2002","unstructured":"Yokoi F, Gr\u00fcnder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 27(2):248\u2013259","journal-title":"Neuropsychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4730-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4730-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4730-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T07:36:30Z","timestamp":1602920190000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4730-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,9]]},"references-count":76,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4730"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4730-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,9]]}}}